预约演示
更新于：2025-06-25
Bempegaldesleukin
贝培阿地白介素
更新于：2025-06-25
概要
基本信息
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)暂停 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 720
来源: *****
关联
22
项与 贝培阿地白介素 相关的临床试验NCT04969861
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined With Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma With PD-L1 Expressing Tumors (PROPEL-36)
NCT04936841
Phase II Study of Bempegaldesleukin (NKTR-214) Together With Palliative Radiation and Anti-PD-1 Checkpoint Blockade in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT04730349
Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)
100 项与 贝培阿地白介素 相关的临床结果
登录后查看更多信息
100 项与 贝培阿地白介素 相关的转化医学
登录后查看更多信息
100 项与 贝培阿地白介素 相关的专利（医药）
登录后查看更多信息
44
项与 贝培阿地白介素 相关的文献（医药）2025-05-01Targeted Oncology
Efficacy of First-Line Treatments for Advanced Renal Cell Carcinoma: A Bayesian Network Meta-analysis of Objective Response, Progression-Free Survival, and Overall Survival
Review
作者: Sundaram, Murali ; Rane, Pratik P ; Burgents, Joseph ; Druyts, Eric ; Yan, Kevin ; Schmidinger, Manuela ; Peer, Avivit
OBJECTIVE:
The purpose of this study was to indirectly compare pembrolizumab + lenvatinib to other treatments of interest for first-line advanced renal cell carcinoma (aRCC).
METHODS:
A systematic literature review searched EMBASE, MEDLINE, and CENTRAL databases for relevant randomized controlled trials of interest up to 30 January 2024, with an updated search conducted on 17 March 2025. A fixed effect Bayesian network meta-analysis (NMA) was conducted to determine the relative treatment effects for overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
RESULTS:
When comparing against other immune checkpoint inhibitors (ICI), a statistically significant improvement in PFS was demonstrated between pembrolizumab + lenvatinib compared with nivolumab + ipilimumab (hazard ratio (HR) = 0.53; 95% credible interval (CrI): 0.40-0.71), avelumab + axitinib (HR = 0.71; 95% Crl: 0.53-0.94), atezolizumab + bevacizumab (HR = 0.54; 95% CrI: 0.40-0.73), and pembrolizumab + axitinib (HR = 0.69; 95% CrI: 0.51-0.91). Treatment with pembrolizumab + lenvatinib resulted in no statistically significant difference between pembrolizumab + lenvatinib and other combination ICI-based therapies for OS. A statistically significant higher ORR was shown for pembrolizumab + lenvatinib compared with nivolumab + ipilimumab (odd ratio (OR) = 3.29; 95% Crl: 2.21-4.93), pembrolizumab + axitinib (OR = 1.92; 95% CrI: 1.27-2.94), atezolizumab + bevacizumab (OR = 4.05; 95% Crl: 2.71-6.05), bempegaldesleukin + nivolumab (OR = 6.20; 95% CrI: 3.69-10.48), and nivolumab (OR = 5.92; 95% CrI: 2.70-13.24).
CONCLUSIONS:
The overall population analysis indicated that pembrolizumab + lenvatinib improves PFS and ORR compared with other approved ICI combination therapies in first-line aRCC. No significant differences in OS were observed between pembrolizumab + lenvatinib and other combination immune checkpoint inhibitor-based therapies.
2025-05-01UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)
Article
作者: De Giorgi, Ugo ; Siefker-Radtke, Arlene O ; Sridhar, Srikala S ; Qureshi, Anila ; Bilen, Mehmet A ; Järvinen, Riikka ; Peer, Avivit ; Balar, Arjun ; Koshkin, Vadim S ; Harputluoğlu, Hakan ; Loriot, Yohann ; Wang, Tianhua ; Poushnejad, Shermeen ; Zalevsky, Jonathan ; Tagliaferri, Mary A. ; Bilen, Mehmet A. ; Vasiliev, Aleksandr ; Penkov, Konstantin ; Castellano, Daniel ; Tagliaferri, Mary A ; Huddart, Robert A. ; Koshkin, Vadim S. ; Huddart, Robert A ; Siefker-Radtke, Arlene O.
BACKGROUND:
In PIVOT-02, bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab (NIVO), a Programmed cell death protein 1 inhibitor, demonstrated the potential to provide additional benefits over immune checkpoint inhibitor monotherapy in patients with urothelial carcinoma, warranting further investigation. We evaluated BEMPEG plus NIVO in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial carcinoma.
METHODS:
This open-label, multicenter, single-arm, phase II study enrolled patients with locally advanced/surgically unresectable or metastatic urothelial carcinoma and who were ineligible for cisplatin-based treatment. Patients received BEMPEG plus NIVO were administered intravenously every 3 weeks for ≤2 years or until progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) by blinded independent central review (BICR) in patients with low programmed death ligand-1 (PD-L1) expression. Secondary endpoints included ORR and duration of response in the overall population. Progression-free survival (PFS) and overall survival (OS) were exploratory endpoints.
RESULTS:
One hundred and eighty-eight patients were enrolled; 123 patients were PD-L1 low (combined positive score [CPS] <10; 65.4%), 59 were PD-L1 high (31.4%; CPS ≥10), and 6 had PD-L1 status unknown (3.2%). ORR per blinded independent central review in patients with PD-L1-low tumors was 17.9% (95% confidence interval [CI] 11.6-25.8) while in all treated patients was 19.7% (95% CI 14.3-26.1). Median PFS and OS in the overall population were 3.0 months and 12.6 months, respectively. BEMPEG plus NIVO combination was well tolerated, with a safety profile similar to previously reported trials; no new or unexpected safety signals were reported.
CONCLUSIONS:
BEMPEG plus NIVO did not meet the efficacy threshold for ORR in patients with previously untreated locally advanced or metastatic urothelial carcinoma and low PD-L1 expression.
2025-04-14CLINICAL CANCER RESEARCH
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Article
作者: Shotts, Kristin M. ; Fairchild, Justin ; Graff, Julie N. ; Wentzel, Kristopher ; Keler, Tibor ; Cabanski, Christopher R. ; Lata, Jennifer ; Galsky, Matthew D. ; Howes, Timothy R. ; Dugan, Ute ; Boffo, Silvia ; Friedlander, Terence W. ; Subudhi, Sumit K. ; Da Silva, Diane M. ; Yellin, Michael J. ; LaVallee, Theresa M. ; Densmore, Julie ; Bhardwaj, Nina ; Chen, Richard O. ; Autio, Karen A. ; Spasic, Marko ; Skolnik, Jeffrey ; O’Donnell-Tormey, Jill ; Fong, Lawrence
Abstract:
Purpose::
Current immune checkpoint therapies offer limited benefits for metastatic castration-resistant prostate cancer. Novel combinations may enhance immunotherapy efficacy.
Patients and Methods::
We conducted an open-label, noncomparative platform trial (NCT03835533) in metastatic castration-resistant prostate cancer to assess nivolumab-based combinations. The cohorts were as follows: (A) bempegaldesleukin 0.006 mg/kg and nivolumab 360 mg i.v. every 3 weeks; (B) stereotactic body radiotherapy 30 to 50 Gy, CDX-301 75 μg/kg s.c. for 5 days, poly-ICLC 1 mg intramuscularly weekly twice for 3 weeks, and nivolumab 480 mg every 4 weeks; and (C) CDX-301 75 μg/kg for 10 days, INO-5151 3 mg intramuscularly on lead-in day 8, day 1 of cycles 1 to 3, and then every 12 weeks, and nivolumab 480 mg every 4 weeks. The primary endpoint was safety; secondary endpoints included composite response rate (radiographic, PSA, or circulating tumor cell responses), 6-month disease control rate, progression-free survival, and overall survival. Serial blood and tissue samples were analyzed for pharmacodynamics and association with disease control.
Results::
A total of 43 patients were enrolled (n = 14, 15, and 14 in cohorts A, B, and C, respectively). Grade 3 to 4 treatment-related adverse events occurred in 10 (71%), 2 (13%), and 2 (14%) patients, respectively, with one grade 5 treatment-related adverse event in cohort A. Composite response rates were 7% (1/14), 33% (5/15), and 7% (1/14). Across cohorts, 6-month disease control was associated with preexisting memory/regulatory T cells, TNFα, and other inflammatory pathways.
Conclusions::
Cohort B, which combined radiotherapy with CDX-301, poly-ICLC, and nivolumab, demonstrated encouraging clinical activity. Preexisting rather than treatment-induced immune activation was associated with clinical benefit across cohorts, highlighting the importance of baseline immune fitness.
103
项与 贝培阿地白介素 相关的新闻（医药）2025-04-16
·靶点圈
细胞疗法临床结果临床研究免疫疗法
2025-02-15
引进/卖出临床3期并购免疫疗法抗体药物偶联物
2025-02-10
免疫疗法抗体药物偶联物临床结果
100 项与 贝培阿地白介素 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈癌转移 | 临床3期 | 美国 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 美国 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 美国 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 奥地利 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 奥地利 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 奥地利 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 希腊 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 希腊 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 希腊 | 2022-03-09 | |
| 头颈癌转移 | 临床3期 | 意大利 | 2022-03-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 623 | Bempegaldesleukin plus Nivolumab | 淵糧醖鹹遞夢獵鬱顧廠(鏇觸範製簾遞積窪顧構) = 製繭齋齋鏇夢夢遞願壓 鏇鏇範淵壓壓鹽鹹鹽築 (憲襯簾獵觸窪範繭願蓋, 18.0 ~ 28.7) 更多 | 不佳 | 2024-08-10 | ||
淵糧醖鹹遞夢獵鬱顧廠(鏇觸範製簾遞積窪顧構) = 選鏇築遞壓憲鏇糧觸製 鏇鏇範淵壓壓鹽鹹鹽築 (憲襯簾獵觸窪範繭願蓋, 25.1 ~ 36.6) 更多 | |||||||
临床1期 | 43 | (Cohort A: NKTR-214 + Nivolumab) | 襯鬱願獵鏇製鹽鹽構鹹 = 鏇築鹹襯窪糧鬱鑰憲製 膚憲繭鬱夢鬱繭鑰醖鏇 (淵衊製繭觸艱淵網顧鹹, 簾範糧鑰觸簾膚窪膚構 ~ 構繭築鏇願憲鬱簾襯顧) 更多 | - | 2024-04-12 | ||
(Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab) | 襯鬱願獵鏇製鹽鹽構鹹 = 夢衊顧齋鹽範獵構鬱選 膚憲繭鬱夢鬱繭鑰醖鏇 (淵衊製繭觸艱淵網顧鹹, 艱築壓繭網夢觸襯膚憲 ~ 觸網網繭願願製積製餘) 更多 | ||||||
临床3期 | 765 | (Nivolumab) | 夢鬱鬱衊窪餘鑰鬱遞觸(艱齋夢憲衊醖願膚衊製) = 憲壓觸簾鏇積夢製簾顧 衊蓋齋觸範窪鑰鹽膚鬱 (襯糧餘鹹製壓積壓蓋獵, 糧願選鹹衊遞願鏇廠積 ~ 繭夢願遞糧構衊餘窪觸) 更多 | - | 2023-04-21 | ||
(Combination of Bempegaldesleukin (NKTR-214) + Nivolumab) | 憲鬱襯選顧壓齋鑰蓋醖(範繭鑰簾艱積遞糧範觸) = 壓製淵廠選窪積簾糧選 觸遞範憲餘鏇簾襯衊醖 (膚繭醖選糧選簾願獵築, 襯鹽壓遞構夢選製衊選 ~ 製鏇積窪簾製鑰壓簾鹽) 更多 | ||||||
临床3期 | 623 | (Combination of Bempegaldesleukin + Nivolumab) | 鹹鹹蓋築艱襯夢憲獵簾 = 鹽憲糧鹽廠鹽顧鏇遞選 鏇範壓淵鑰糧築遞艱繭 (窪憲積醖鑰蓋鬱淵築選, 構窪憲膚餘蓋窪鏇憲網 ~ 壓範醖鏇窪糧願範糧積) 更多 | - | 2023-04-11 | ||
(Sunitinib or Cabozantinib) | 鹹鹹蓋築艱襯夢憲獵簾 = 繭襯艱範齋構齋齋築範 鏇範壓淵鑰糧築遞艱繭 (窪憲積醖鑰蓋鬱淵築選, 糧鏇鹽選廠蓋繭憲夢積 ~ 艱觸齋鹽齋願積構齋觸) 更多 | ||||||
临床1/2期 | 15 | (Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg)) | 壓醖膚繭鹽夢糧構窪觸 = 膚蓋餘獵壓網窪衊遞醖 簾鬱憲顧選襯獵艱網憲 (範夢衊構艱觸醖築齋廠, 窪淵窪積製壓憲獵憲顧 ~ 築餘鬱夢蓋鑰窪鬱憲衊) 更多 | - | 2023-03-24 | ||
(Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg)) | 壓醖膚繭鹽夢糧構窪觸 = 網獵觸鏇網淵憲製淵糧 簾鬱憲顧選襯獵艱網憲 (範夢衊構艱觸醖築齋廠, 齋艱繭簾鹽壓範積鬱齋 ~ 鹹構餘夢夢觸網顧糧製) 更多 | ||||||
临床2/3期 | 1 | (BEMPEG + Pembrolizumab) | 選膚獵構蓋鏇築鏇製餘(壓衊顧淵淵醖餘淵夢製) = 鬱蓋糧衊鹹壓選廠願積 窪製夢獵鹹簾鏇壓壓餘 (蓋選膚鑰衊鬱鬱鬱顧蓋, 齋簾繭餘觸鏇顧蓋醖窪 ~ 廠醖網淵鹹獵製顧網廠) 更多 | - | 2022-12-15 | ||
(Pembrolizumab Monotherapy) | 選膚獵構蓋鏇築鏇製餘(壓衊顧淵淵醖餘淵夢製) = 膚鏇鏇艱獵製窪構遞遞 窪製夢獵鹹簾鏇壓壓餘 (蓋選膚鑰衊鬱鬱鬱顧蓋, 衊壓選遞築獵齋鑰築壓 ~ 鏇廠觸鏇願膚獵廠鏇製) 更多 | ||||||
临床3期 | 不可切除的黑色素瘤 Tregs | IFNγ | - | BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W | 觸積遞鑰鹹積範獵築築(廠鹽艱簾構選鹹鹽遞餘) = 壓願選襯顧繭製膚願壓 膚顧壓鹹衊齋餘遞淵糧 (築簾艱網選醖醖獵範簾 ) 更多 | 不佳 | 2022-11-07 | |
NIVO 360 mg IV Q3W | 觸積遞鑰鹹積範獵築築(廠鹽艱簾構選鹹鹽遞餘) = 簾蓋繭遞襯遞繭築蓋窪 膚顧壓鹹衊齋餘遞淵糧 (築簾艱網選醖醖獵範簾 ) 更多 | ||||||
临床3期 | 晚期肾细胞癌 一线 | 509 | 獵憲窪網壓窪鹽簾蓋艱(襯築艱襯憲鹽鏇鑰製蓋) = 網獵醖願壓觸蓋憲艱艱 鹽淵觸窪襯壓鏇鏇淵觸 (築餘鑰簾範憲蓋艱鏇夢 ) 更多 | 不佳 | 2022-09-12 | ||
獵憲窪網壓窪鹽簾蓋艱(襯築艱襯憲鹽鏇鑰製蓋) = 壓製夢鬱壓網艱遞遞壓 鹽淵觸窪襯壓鏇鏇淵觸 (築餘鑰簾範憲蓋艱鏇夢 ) 更多 | |||||||
临床3期 | 783 | 選鬱憲製範醖憲鹽蓋鑰(範築積簾遞願鹽鏇構鬱) = 艱製積鏇糧憲構衊鑰淵 鹹鏇顧構艱廠憲獵選願 (憲壓構廠積餘繭簾淵糧 ) 更多 | 不佳 | 2022-09-10 | |||
選鬱憲製範醖憲鹽蓋鑰(範築積簾遞願鹽鏇構鬱) = 願築膚衊憲窪繭艱鹹顧 鹹鏇顧構艱廠憲獵選願 (憲壓構廠積餘繭簾淵糧 ) 更多 | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 41 | 願顧鹹蓋繭窪淵壓窪憲(範鑰繭積鏇窪廠憲餘襯) = 壓鏇糧淵鬱膚願衊網繭 憲壓淵壓選膚齋願築遞 (衊壓醖製窪鏇鹹鏇糧構 ) 更多 | 积极 | 2022-05-25 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用